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Abstract
Background—Studies have found associations between cancer therapies and auditory
complications, but data are limited on long-term outcomes and risks associated with multiple
exposures.
Procedure—The Childhood Cancer Survivor Study is a retrospective cohort investigating health
outcomes of long-term survivors (5+ years) diagnosed and treated between 1970 and 1986
compared to a randomly selected sibling cohort. Questionnaires were completed by 14,358
survivors of childhood cancer and 4,023 sibling controls. Analysis determined the first occurrence
of four auditory conditions in two time periods: diagnosis to ≥ 5 years post diagnosis, and > 5
years post diagnosis. Multivariable analyses determined the relative risks (RR) and 95%
confidence interval (CI) of auditory conditions by treatment exposure.
Results—Five or more years from cancer diagnosis, survivors were at increased risk of problems
hearing sounds (RR=2.3; 95% CI: 1.8–2.8), tinnitus (RR=1.7; 95% CI: 1.4–2.1), hearing loss
requiring an aid (RR=4.4; 95% CI: 2.8–6.9), and hearing loss in 1 or both ears not corrected by a
hearing aid (RR=5.2; 95% CI: 2.8–9.5), when compared to siblings. Temporal lobe and posterior
fossa radiation was associated with these outcomes in a dose-dependent fashion. Exposure to
platinum compounds was associated with an increased risk of problems hearing sounds (RR=2.1;
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95% CI: 1.3–3.2), tinnitus (RR=2.8; 95% CI: 1.9–4.2), and hearing loss requiring an aid (RR=4.1;
95% CI:2.5–6.7)
Conclusions—Childhood cancer survivors are at risk of developing auditory complications.
Radiation and platinum compounds are determinants of this risk. Follow-up is needed to evaluate
the impact of auditory conditions on quality of life.
Keywords
late effects of therapy; radiation therapy
Introduction
Due to improvements in therapeutic modalities and supportive care, the overall survival rate
for childhood cancer is approximately 80%1–2. Accordingly, there has been an interest in
and emphasis on the burden of cure that survivors face. Research has shown that long-term
survivors are at increased risk for morbidity and early mortality3. A study by Oeffinger et al.
found that approximately two-thirds of childhood cancer survivors report at least one
chronic health condition and many have multiple and/or severe chronic conditions4.
Although the majority of childhood cancer survivors consider their quality of life to be good,
some late effects can have an adverse impact.5 Development of complications of therapy
depends on many factors, including the type and cumulative dose of chemotherapeutic
agents, age at therapy, and whether radiation was part of the treatment plan2,6.
Hearing loss is a well-reported complication of cancer treatment6–9. These late
complications not only create functional limitation in survivors, but also potentially impact
other arenas, such as speech development, educational attainment, and socialization.9
Platinum chemotherapy agents may cause hearing deficits, ranging from reversible tinnitus
to permanent hearing loss8,–10. Cisplatin ototoxicity is characterized as bilateral,
irreversible, and progressive sensorineural hearing loss8–9,11–12. Carboplatin does not
routinely cause hearing loss, but may when given in combination with cisplatin or in high
doses11, 13–16. Larger individual and cumulative doses, the presence of a brain tumor, and
young patient age are considered risk factors for developing cisplatin-induced otoxicity8–
9,11,17. Additionally, studies suggest that prior cranial radiation may enhance the ototoxicity
of platinum compounds.17–20
Radiation therapy to the head and/or neck can damage the auditory apparatus, leading to
both conductive and sensorineural hearing loss. 9,21 The severity of radiation-induced
ototoxicity is determined by the total dose, with most toxicity seen at doses greater than 30
Gy. 9,22–23 In addition, patients with ventriculoperitoneal (VP) shunts experience changes
in intracranial pressure that can cause or increase the risk of hearing loss22. There is
evidence that the incidence of clinically significant hearing loss from radiation is relatively
low and manifestation may require long-term follow-up22.
This study from the Childhood Cancer Survivor Study (CCSS) reports the results of an
analysis of the long-term effects of cancer and its associated therapies on hearing. Primary
aims were to describe the risk of self-reported hearing complications as a function of
survivors’ clinical and demographic characteristics and time since diagnosis; to compare the
rates of these hearing complications in survivors and a sibling control group; and to evaluate
the effect of specific cancer treatments on the risk of developing late hearing complications
five years post diagnosis.
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Methods
Patient Selection and Contact
The CCSS is a multi-institutional collaborative retrospective study of individuals who
survived at least 5 years after diagnosis of cancer during childhood or adolescence. The
current analysis is limited to subjects who met the following criteria: 1.) diagnosis of
leukemia, kidney tumor, bone tumor, soft tissue sarcoma, neuroblastoma, Hodgkin disease,
non-Hodgkin lymphoma, or primary central nervous system malignancy of any histologic
subtype; 2) diagnosis and treatment at one of 26 collaborating institutions; 3) diagnosed
between January 1, 1970 and December 31, 1986; 4) age less than 21 years old at diagnosis ;
5) survival greater than or equal to 5 years from diagnosis. 24–25
The CCSS research protocol and subject contact documents were approved by the Human
Subjects Committees at participating institutions. In 1994, a self-administered baseline
questionnaire was sent to eligible participants. This questionnaire contained queries
pertaining to demographical information, health habits, medical diagnoses, surgical
procedures, and other health outcomes. The survey can be found at the CCSS website
(http://ccss.stjude.org).
Of the 20,691 eligible 5 year survivors, 3,058 (14.8%) were lost to follow-up. Of the
remaining 17,633 cases contacted, 14,358 (81.4%) completed the baseline questionnaire and
3,210 (18.2%) declined participation. Of the participants, 13,247 (92.3%) signed permission
to abstract information from their medical records and complete treatment information was
obtained for 12,592. Therefore, this report on auditory conditions in childhood cancer
survivors is based on 14,358 survivors who completed the baseline questionnaire, with
analysis of treatment based on 12,592 survivors with available medical records.
Nearest age siblings of randomly selected participants were invited to participate as the
control population. Of the 4,869 siblings contacted, 4023 (82.6%) completed the
questionnaire. Table I illustrates the demographic and treatment information for 14,358
survivors and 4023 siblings.
Auditory complications in this analysis included self-reported hearing loss requiring a
hearing aid (hearing loss), hearing loss in 1 or both ears not corrected by a hearing aid
(deafness), tinnitus or ringing in the ears (tinnitus), and problems hearing sounds, words, or
language in crowds (problems hearing sounds). The questions were introduced with "Have
you ever been told by a doctor or other health care professional that you have, or have
had. . ." Possible responses were “yes”, “no”, and “not sure”. If the respondent answered
“yes”, they were asked to indicate the age at first occurrence of the condition.
Treatment Information
All participating survivors were asked to sign a consent form allowing information to be
obtained from their medical records. For the survivors who returned a signed consent form,
information was abstracted from their medical records. The information obtained included
chemotherapy, radiation and surgery for their initial therapy, salvage therapy for recurrent
disease, and bone marrow transplant preparative regimens (if applicable). Detailed treatment
information was abstracted and included exposure to 42 chemotherapeutic agents with
cumulative doses for 22 specific agents.
This chemotherapy information was used to assess cisplatin and carboplatinum use as a
dichotomous outcome, and as part of a platinum compound cumulative dose. A platinum
compound cumulative dose was calculated by summing the cisplatin dose and one-fourth of
the carboplatinum dose 26.
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Within the CCSS, radiation records were obtained for 8507 patients. Details including
treatment dose and body area treated were abstracted in the 5 year time period from
diagnosis to capture treatment relevant to the primary tumor. Data on the 1% of survivors
(n=134) who received some radiation exposure beyond the 5 year cutoff was not included in
this analysis. To quantify radiation exposure to the cochlea, maximum treatment doses were
summarized for two segments of the brain, posterior fossa and temporal lobe. A brain
segment was considered to be in the radiation field if at least half of the segment was
included in the primary radiation volume. If there was no direct treatment to the brain
segment, dose was classified into high and low scatter categories based on proximity of the
treated region to the segment in question. The high scatter category was assigned if the
nearest treatment included other regions of the head or brain. The low scatter category was
assigned if the nearest treatment was not in the head or brain. Individual scatter doses were
not estimated. Based on measurements of radiation falloff with distance and known
treatment dose ranges, high scatter doses ranged from approximately 1 to 5 Gy and low
scatter doses ranged from approximately >0 to1 Gy.27
Surgical information from medical records was reviewed for indications of VP shunts (ICD9
codes 2.34, 2.42, or 2.43). The baseline questionnaire also asked if the participant had ever
had a VP shunt. This information was used to create a dichotomous VP shunt variable for
analysis. The medical record abstraction form is available at http://ccss.stjude.org
Data Analysis
Multiple imputation methodology was used in the event that a survivor or sibling reported a
condition but not the age at first occurrence. Ten imputed values for each missing age were
generated via the EM algorithm using a slightly modified version of the technique of Taylor
et al. 28–29 Gender, age, primary diagnosis, radiation therapy, and platinum compound
exposure were used in the imputation model for the rate of development of each auditory
condition, with the effects of therapy allowed to change across the time periods. The
imputation model for siblings did not include diagnosis or treatment information. Reported
analytic results were obtained by combining analyses across the imputed data sets using
standard formulas.28
The prevalence ratio (PR) at study entry was estimated by dividing the observed count of the
condition among survivors by an expected count for the period from diagnosis to 5 years
based on rates calculated from same age and gender siblings. Statistical inference was based
on bootstrap samples, i.e. using 100 resamples of the observed data (with replacement) to
calculate the prevalence ratio 100 times and form an approximate distribution of the
estimator. The standard deviation of the distribution was used as the standard error of the
PR.
The relative risks (RR) for developing each condition 5 or more years post-diagnosis,
comparing the survivors to the siblings, as well as incidence rates per 1000 person-years
were estimated by multivariable Poisson regression30. Models were adjusted for gender and
for age, with potential within-family correlation accounted for using generalized estimating
equations31.
To assess the effect of therapy on the risk of developing auditory conditions, multivariable
Cox proportional hazard models were used among survivors to determine relative risk for
each condition. Models assessed the effect of radiation therapy, use of platinum drugs and
VP shunt, adjusting for gender and age at diagnosis. Age was used as the time scale, with
subjects entering the risk set at five years post diagnosis.
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To determine risk as a function of radiation dose, separate Cox models were fit using
maximum dose to the posterior fossa and temporal lobe segments of the brain, adjusting for
age at diagnosis, gender, platinum compound use, and VP shunt. Additional models treating
platinum compound cumulative dose as categorical (None, 1–349 mg/m2, 350 mg/m2 or
more) revealed interactions between platinum dose and high dose radiation for the
conditions ‘hearing loss’ (p-value=.0101) and ‘deafness’ (p-value=.0605). The models were
stratified on radiation dose of 50 Gy or more, resulting in two estimates of risk for these
conditions. Cumulative incidence curves, starting with the 5-year anniversary of the primary
cancer diagnosis, were constructed using the method described in Gooley et al 32 treating
death as a competing risk for the outcome.
RESULTS
Table I describes the demographics of the cohorts (eligible survivors and control group
siblings) used in this analysis. There was a slight male predominance in the survivor group
compared to the sibling control group (53.7% compared with 48.1%). Survivors were
younger than siblings, with 77.5% less than 30 years old compared to 62.4%. Over 60% of
the survivors were less than 10 years of age at diagnosis. Leukemia was the most common
diagnosis among survivors. For cases that survived five years but subsequently died
(14.1%), selected baseline information was requested from a family member, usually the
parent.
Reported Occurrence of Auditory Conditions and Relative Risk Compared to Siblings
Table II shows the frequencies of auditory complications and comparison to siblings of first
occurrence of self-reported auditory conditions by two time periods: prevalence ratio at 5
years post-diagnosis, and the prospective incidence rate and relative risk 5 years or more
post-diagnosis. The relative rate of first occurrence of all conditions was greatest in the time
period from diagnosis to 5 years post-diagnosis. However, during the period 5 years or more
post-diagnosis, the risk among survivors remained significantly higher (p <0.01) relative to
siblings for all conditions.
Diagnosis and Treatment-Related Factors for Specific Conditions Occurring 5 Years or
More Post-Diagnosis
Problems hearing sounds in crowds was associated with prior treatment with any platinum
drug (RR=2.1; 95% CI: 1.3–3.2, Table III) and exposure to posterior fossa or temporal lobe
radiation (RR=1.7; 95% CI: 1.3–2.2). All radiation doses other than low scatter to the
temporal lobe and the posterior fossa were associated with a statistically significant
increased risk of problems hearing sounds compared to those with no radiation to those
areas (Table IV). When cumulative dose of platinum compound exposure was explored,
there was an increased risk of problems hearing sounds for those treated with 1–349 mg/m2
(RR=2.1: 95% CI: 1.1– 4.1 Table V) and greater than or equal to 350 mg/m2 (RR=1.9; 95%
CI: 1.0–3.5). When analyzing the effect of diagnosis on the risk of problems hearing sounds,
it was found that the 20 year cumulative incidence was greatest for primary CNS tumor
survivors (cumulative incidence= 11.4%; 95% CI: 9.4–13.5) and Hodgkin lymphoma
survivors (cumulative incidence= 4.2%; 95% CI: 3.0–5.4) (Table VI). The cumulative
incidence of self-reported problems hearing sounds continued to increase up to 20 years
after diagnosis for survivors who received radiation to the posterior fossa or temporal lobe
(Figure 1) and up to 15 years after diagnosis for those who were treated with platinum
chemotherapy agents (Figure 2).
Survivors exposed to platinum drugs had an increased risk of tinnitus occurring 5 years or
more after diagnosis (RR=2.8; 95% CI: 1.9–4.2). In addition, radiation to the temporal lobe
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and posterior fossa in doses of 30 Gy or higher was associated with an increased risk of
tinnitus (RR=2.4; 95% CI: 1.6–3.6 and RR=2.6; 95% CI: 1.7–4.1 for 30–49.9 Gy,
respectively) as compared to subjects with no radiation to those areas. Platinum compound
doses ranging from 1–349 mg/m2 as compared to 0 mg/m2 were associated with tinnitus
(RR=3.8; 95% CI: 2.2–6.8). At 20 years post-diagnosis, self-reported complaints of tinnitus
were most frequent in survivors of a primary CNS malignancy (cumulative incidence=
7.4%; 95% CI: 5.7–9.2) and soft tissue sarcoma survivors (cumulative incidence= 4.0%;
95% CI: 2.6–5.3). The cumulative incidence of tinnitus continued to increase up to 20 years
post-diagnosis for survivors who received at least 30 Gy of radiation to either the posterior
fossa or temporal lobe (Fig 1) and up to 15 years after diagnosis for those who were treated
with platinum chemotherapy agents (Fig 2).
Platinum drug exposure increased the risk of hearing loss requiring a hearing aid in
survivors (RR=4.1; 95% CI: 2.5–6.7), as did radiation to the posterior fossa or temporal lobe
(RR=2.2; 95% CI 1.4–3.5). The risk of hearing loss increased as dose to the temporal lobe
(RR=10.5; 95% CI: 5.9–18.4 for 50+ Gy vs. 0 Gy) and posterior fossa (RR=11.7; 95% CI:
6.5–21.0 for 50+ Gy vs. 0 Gy) increased. In survivors who received < 50 Gy of radiation to
the temporal lobe or posterior fossa, exposure to platinum chemotherapy agents increased
the risk of hearing loss in a dose- dependent fashion (RR=11.0; 95% CI: 5.2–23.2 for 350+
mg/m2 vs. 0 mg/m2). Twenty years after diagnosis, survivors of primary CNS malignancies
were most likely to report this condition (cumulative incidence= 6.2; 95% CI: 4.7–7.7). Self-
reported hearing loss continued to increase up to 25 years post diagnosis for survivors who
received at least 30 Gy of radiation to the posterior fossa or temporal lobe (Fig 1) and up to
15 years after diagnosis for those who were treated with platinum chemotherapy agents (Fig
2). Survivors who were less than 5 years of age at diagnosis were more likely to report
hearing loss than subjects age 15–20 (RR 3.1; 95% CI: 1.4–7.1, data not shown).
Hearing loss in one or both ears not corrected by a hearing aid was associated with radiation
to the posterior fossa or temporal lobe. Doses of radiation to the temporal lobe that were ≥
30 Gy were associated with this complication (RR=7.5; 95% CI: 3.6–15.5 for 50+ Gy vs. 0
Gy). In survivors who received radiation to the posterior fossa, the risk of deafness was
greatest for those receiving at least 50 Gy (RR 10.7; 95% CI: 5.2–22.2), but was also noted
at doses of 30–49.9 Gy compared to no radiation to the posterior fossa. While platinum
chemotherapy drug use was not associated with deafness when the entire cohort was
analyzed, a sub-group analysis revealed a dose dependent relationship in survivors who
received platinum agents and <50 Gy of radiation to the posterior fossa or temporal lobe
(RR=5.4; 95% CI: 1.6–18.2 for 350+ mg/m2 vs. 0 mg/m2). This condition was reported most
frequently by survivors of primary CNS malignancies at 20 years post-diagnosis (cumulative
incidence= 5.0; 95% CI: 3.7–6.3). Survivors continued to report deafness up to 15 years
after diagnosis for those treated with ≥ 50 Gy of radiation to the posterior fossa or temporal
lobe and up to 20 years post diagnosis for those treated with 30–49.9 Gy of radiation to the
posterior fossa or temporal lobe (Fig 1) and in survivors who were treated with platinum
chemotherapy agents up to 10 years after diagnosis (Fig 2).
DISCUSSION
Previous studies have investigated ototoxicity in children who received platinum
chemotherapy and/or cranial radiation. 8–9,11,19,20,22,23 Many have been limited to certain
diseases, such as nasopharyngeal carcinoma, neuroblastoma, and brain tumors.16,22,23,33,34
In part due to different grading systems and variability in reporting hearing loss, there has
been a great deal of variation in estimates of the incidence of hearing loss after cisplatin
therapy in the pediatric population, with ranges in the literature from 11–97%14. In addition,
the majority of reported studies regarding ototoxicity have relatively short follow-up and
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there is evidence that hearing deficits from therapy may worsen with time or have a latency
period prior to manifestation11,15,22,23,35. The current study, while relying on self-reported
auditory outcomes, adds to current knowledge by providing estimates from a large and
diverse cohort of survivors who reported a first occurrence of auditory complications 5 years
or greater post-diagnosis, and with follow-up spanning up to 25 years.
The CCSS is an invaluable resource for the identification of late effects that first occur many
years after the original diagnosis. The make-up of this cohort is representative of the cancer
incidence and 5 year survival rates of the eight major pediatric cancers eligible and treated
during the treatment era (1970–1985). Due to limited resources, however, survivors of more
rare malignancies, such as germ cell tumors and nasopharyngeal carcinomas, were not
included in the CCSS cohort. It is important to note that the new CCSS cohort is currently
accruing patients who were treated between 1987–1999 and will allow further investigation
into sequelae faced by survivors treated with more current treatment regimens. This will be
especially important in studying the late effects in survivors of primary CNS malignancies,
as their regimens have been modified and survival rates have improved.
This study confirmed that treatment with platinum compounds has adverse effects on
hearing, as it was associated with a risk of problems hearing sounds, tinnitus, and hearing
loss requiring a hearing aid. The mechanism of cisplatin toxicity involves deterioration of
the outer hair cells of the Organ of Corti in the cochlea15,36 , while carboplatin affects the
inner hair cells of the Organ of Corti13. This progressive loss of hair cells occurs due to
intracellular production of reactive oxygen species and iron-induced free radicals, which
deplete the cells of anti-oxidants15. Sensorineural hearing loss is a known complication of
platinum drugs, but hearing loss affecting only the higher frequencies is difficult to
appreciate as it manifests with impaired recognition of high frequency consonants (such as s,
f, k) and difficultly in hearing the plural forms of words9, 11. Problems hearing sounds and
tinnitus may be surrogate markers of sensorineural hearing loss, as they are often symptoms
of the underlying damage to the auditory apparatus37–39. Although cumulative platinum
compound dosing was analyzed in relation to auditory complications, with the exception of
hearing loss requiring a hearing aid and deafness in a subset of survivors who received <50
Gy of radiation to the temporal lobe or posterior fossa, there was no dose response in the
risk of late-occurring hearing conditions. This study supports earlier reports that indicate that
while ototoxicity secondary to platinum compounds often develops soon after treatment36,
there is a risk of progression or new onset ototoxicty greater than 5 years after therapy11,15.
Not unexpectedly, radiation to the temporal lobe and/or posterior fossa resulted in an
increased risk of problems hearing sounds, tinnitus, hearing loss requiring a hearing aid, and
hearing loss in 1 or both ears not corrected by a hearing aid. Radiation may affect the
external ear, causing otitis externa and stenosis of the external auditory canal. The middle
ear can manifest radiation toxicity through eustachian tube dysfunction, leading to chronic
otitis media with effusion. In addition, perforation or sclerosis of the tympanic membrane
may occur. These changes can cause transient or permanent conductive hearing loss.
Radiation effects on the inner ear may lead to tinnitus, labyrinthitis, vertigo, and
sensorineural hearing loss due to damage to the cochlea and retro-cochlear component of the
auditory apparatus7,21. Radiation damage often occurs within 6–12 months of treatment33,
but this study shows that survivors more than 5 years post-diagnosis remain at risk for the
development of ototoxicity. In addition, although the majority of toxicity seen with radiation
occurred at doses ≥ 30 Gy, problems hearing sounds was seen at doses <30 Gy, indicating
that close audiologic follow-up is called for in all survivors who received radiation to the
posterior fossa or temporal lobe.
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It is important to note that two demographic groups stood out as particularly vulnerable to
audiologic complications: survivors of primary CNS malignancies and those survivors who
were diagnosed at less than 5 years of age. Radiation is often part of the therapy for primary
CNS malignancies and now platinum compounds are often utilized, exposing survivors to
multiple ototoxic treatments. It is also possible that the hearing loss is in addition to
cognitive late effects of therapy, thereby putting the survivor at increased risk of impaired
quality of life. In addition, survivors who were less than 5 years of age at diagnosis were
found to have an increased risk of hearing loss requiring a hearing aid. This fact stresses the
need for close audiologic follow-up in survivors who were treated at a very young age and
who may be at increased risk for adverse educational and psychosocial sequelae.
It is also notable that survivors of Hodgkin lymphoma had an increased cumulative
incidence of problems hearing sounds at 20 years post diagnosis. With the exception of
certain salvage therapies, this population is not routinely exposed to platinum chemotherapy
agents. It is likely that the report of problems hearing sounds is related to neck radiation that
some survivors received. This finding is worth further follow-up, as some response based
treatment protocols for Hodgkin lymphoma are intensifying therapy with the addition of
cisplatin to slow responders.
There is evidence that pre-irradiation cisplatin is associated with less risk of ototoxicity than
when cisplatin is given during or after radiation17,19. We attempted to confirm that finding;
however, few patients during the time period from 1970–1986 were treated with pre-
irradiation cisplatin. It was not until later years that cisplatin was routinely used in brain
tumor patients.
This study is not without limitations. The use of temporal lobe and posterior fossa radiation
dosage as a surrogate for dosage to the cochlea is not ideal and more precise information
about the dosage the cochlea received would have been preferred. Some of the auditory
conditions studied could overlap, resulting in a survivor answering yes to multiple
conditions. The data available on this large cohort is limited to self-reported auditory
outcomes, which may result in either under or over-reporting of some conditions. However,
reliability of selected self-reported conditions among stem cell transplant survivors has been
demonstrated to be good40.
In summary, survivors of childhood cancer are at increased risk for auditory late effects.
This risk is multifactorial, based in part on treatment factors, age at diagnosis, and the
underlying diagnosis. This report documents that hearing loss can occur or progress more
than 5 years after diagnosis and supports continued audiologic follow-up of survivors who
were treated with platinum compounds or radiation, especially those who were less than 5
years of age at diagnosis and those treated for primary CNS malignancies. Hearing loss is
not only a medical complication, but may influence speech development, educational
achievement, and social-emotional maturation. 11,41. Early detection of auditory impairment
and intervention may decrease the risk of adverse psychosocial outcomes. Continued follow-
up of childhood cancer survivors is needed to evaluate the future occurrence of auditory
impairment among an aging population and to evaluate the impact of complications on
quality of life.
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Figure 1.
Cumulative incidence (%) of conditions based on maximum radiation to temporal lobe or
posterior fossa.
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Figure 2.
Cumulative incidence (%) of conditions by use of platinum drugs (cisplatin or carboplatin).
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